Analyzing Xenetic Biosciences (XBIO) & Its Rivals
Xenetic Biosciences (NASDAQ: XBIO) is one of 282 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Xenetic Biosciences to similar companies based on the strength of its valuation, risk, institutional ownership, dividends, earnings, profitability and analyst recommendations.
This table compares Xenetic Biosciences and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Xenetic Biosciences Competitors||-5,339.53%||-435.75%||-40.79%|
This is a breakdown of recent ratings for Xenetic Biosciences and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Xenetic Biosciences Competitors||808||3172||11491||230||2.71|
Xenetic Biosciences currently has a consensus price target of $10.00, indicating a potential upside of 342.48%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.21%. Given Xenetic Biosciences’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Xenetic Biosciences is more favorable than its competitors.
Volatility & Risk
Xenetic Biosciences has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500. Comparatively, Xenetic Biosciences’ competitors have a beta of 7.39, suggesting that their average share price is 639% more volatile than the S&P 500.
Earnings and Valuation
This table compares Xenetic Biosciences and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Xenetic Biosciences||$3.00 million||-$54.20 million||-1.82|
|Xenetic Biosciences Competitors||$286.20 million||$34.74 million||142.32|
Xenetic Biosciences’ competitors have higher revenue and earnings than Xenetic Biosciences. Xenetic Biosciences is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
3.8% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 48.9% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 7.9% of Xenetic Biosciences shares are held by company insiders. Comparatively, 17.3% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Xenetic Biosciences competitors beat Xenetic Biosciences on 7 of the 12 factors compared.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company’s technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company’s lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII.
Receive News & Ratings for Xenetic Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.